Zobrazeno 1 - 4
of 4
pro vyhledávání: '"sarath chandra mouli veeravalli"'
Autor:
Charles Adhav, Ann Wouters, Amit V. Thorat, Arvind Chopra, Sarath Chandra Mouli Veeravalli, Vineeta Shobha, Kenneth Kwok, Shrikant Wagh, Wei Yu, Srikantiah Chandrashekara, Uppuluri R. Rao, Jugal Kishore Kadel, Paul V. Santos Estrella, Sapan Pandya, Reena Sharma
Publikováno v:
International Journal of Rheumatic Diseases
Objectives Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We characterized tofacitinib efficacy/safety in Indian vs rest of the world (ROW; excluding India) RA patients. Methods Efficacy data were pooled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af5f031f35645aae6fe2172695e4cee6
https://doi.org/10.1111/1756-185x.13853
https://doi.org/10.1111/1756-185x.13853
Autor:
BG Dharmanand, Ramakrishna Rao Uppuluri, Siddharth Kumar Das, Sarath Chandra Mouli Veeravalli, Elizabeth C. Hsia, Ahmed Khalifa, Sarvajeet Pal, R. Yao, Milind Nadkar, Kaiyin Fei, Vineeta Shobha
Publikováno v:
International Journal of Rheumatic Diseases. 19:1083-1092
Aim To conduct a subgroup analysis of GO-MORE trial Part 1, comparing efficacy and safety of add-on subcutaneous golimumab therapy in rheumatoid arthritis (RA) patients enrolled from and outside India. Methods GO-MORE was an open-label, multicenter,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39a2a7ce79ea8a085ba249a7305804d6
https://doi.org/10.1111/1756-185x.12927
https://doi.org/10.1111/1756-185x.12927
Publikováno v:
Chest. 156:A1766
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cc098cb8a46a2b19bf5cf523f835125
https://doi.org/10.1016/j.chest.2019.08.1537
https://doi.org/10.1016/j.chest.2019.08.1537
Publikováno v:
In Chest October 2019 156(4) Supplement:A1766-A1766